Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neur… Read more
Neurizon Therapeutics Ltd (NUZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.501x
Based on the latest financial reports, Neurizon Therapeutics Ltd (NUZ) has a cash flow conversion efficiency ratio of -0.501x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-5.12 Million) by net assets (AU$10.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neurizon Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Neurizon Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neurizon Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurizon Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bitcoin Well Inc.
OTCQB:BCNWF
|
0.195x |
|
DRA Global Ltd
AU:DRA
|
-0.008x |
|
Ta Yih Industrial Co Ltd
TW:1521
|
0.038x |
|
MANOLETE PARTNERS LS-004
F:2BE
|
N/A |
|
Gold Pacific Co. Ltd
KQ:038530
|
0.000x |
|
Coheris SA
PA:COH
|
0.235x |
|
GTPL Hathway Limited
NSE:GTPL
|
0.101x |
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
0.248x |
Annual Cash Flow Conversion Efficiency for Neurizon Therapeutics Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Neurizon Therapeutics Ltd from 2003 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$2.82 Million | AU$-14.29 Million | -5.067x | -902.78% |
| 2024-06-30 | AU$10.23 Million | AU$-5.17 Million | -0.505x | -25.64% |
| 2023-06-30 | AU$3.89 Million | AU$-1.56 Million | -0.402x | -17.63% |
| 2022-06-30 | AU$3.90 Million | AU$-1.33 Million | -0.342x | -185.95% |
| 2021-06-30 | AU$7.84 Million | AU$-937.97K | -0.120x | +16.39% |
| 2020-06-30 | AU$8.88 Million | AU$-1.27 Million | -0.143x | +21.54% |
| 2019-06-30 | AU$8.53 Million | AU$-1.55 Million | -0.182x | +12.37% |
| 2018-06-30 | AU$7.46 Million | AU$-1.55 Million | -0.208x | -18.24% |
| 2017-06-30 | AU$7.14 Million | AU$-1.26 Million | -0.176x | +23.97% |
| 2016-06-30 | AU$6.92 Million | AU$-1.60 Million | -0.231x | +33.64% |
| 2015-06-30 | AU$5.02 Million | AU$-1.75 Million | -0.349x | -94.01% |
| 2014-06-30 | AU$8.84 Million | AU$-1.59 Million | -0.180x | +12.16% |
| 2013-06-30 | AU$7.76 Million | AU$-1.59 Million | -0.205x | -21.50% |
| 2012-06-30 | AU$1.81 Million | AU$-305.46K | -0.168x | +91.19% |
| 2011-06-30 | AU$254.90K | AU$-487.30K | -1.912x | -51.61% |
| 2010-06-30 | AU$1.15 Million | AU$-1.45 Million | -1.261x | -1442.47% |
| 2009-06-30 | AU$5.81 Million | AU$-474.73K | -0.082x | +38.00% |
| 2008-06-30 | AU$5.86 Million | AU$-772.26K | -0.132x | +67.42% |
| 2007-06-30 | AU$5.91 Million | AU$-2.39 Million | -0.405x | +31.02% |
| 2006-06-30 | AU$7.69 Million | AU$-4.51 Million | -0.587x | -47.87% |
| 2005-06-30 | AU$7.69 Million | AU$-3.05 Million | -0.397x | +15.63% |
| 2004-06-30 | AU$3.87 Million | AU$-1.82 Million | -0.470x | +70.02% |
| 2003-06-30 | AU$741.02K | AU$-1.16 Million | -1.568x | -- |